maaf email atau password anda salah

Other Tempo Media
Majalah Tempo
Koran Tempo
Tempo.co
Subscribe

The Efficacy Roller Coaster

Monday, January 18, 2021

The temporary results of the Sinovac vaccine’s clinical trials only contain data from 33 percent of participants. There is concern over transparency.

 

arsip tempo : 177611522392.

. tempo : 177611522392.

THE 20-page interim report on the third phase of the Sinovac vaccine’s clinical trials was submitted by the University Padjadjaran (Unpad) Medical School’s research team in Bandung, West Java, to Bio Farma on Thursday night, January 7. The report, which was submitted by the Unpad team’s manager, Eddy Fadlyana, and forwarded to the Food and Drug Monitoring Agency (BPOM), was the bases for issuing an emergency use authorizati

...

Subscribe to continue reading.
We craft news with stories.

For the benefits of subscribing to Digital Tempo, See More

The Best Choice

Rp 750.000/12 months

  • *Flexible payment methods
  • *Unlimited access to Tempo Plus & Tempo Magz
Subscribe

Rp 386.280/6 months

  • *Auto-renews every 6 months
  • *Cancel at anytime
  • *Unlimited access to Tempo Plus & Tempo Magz
Subscribe

See Other Packages

Already a Subscribed? Log in here
To receive daily news by Email, Sign up for Tempo ID.

Devy Ernis

Vaksin Sinovac
Prev Next

More Articles

More exclusive contents

  • April 13, 2026

  • April 6, 2026

  • March 30, 2026

  • March 23, 2026

Independent journalism needs public support. By subscribing to Tempo, you will contribute to our ongoing efforts to produce accurate, in-depth and reliable information. We believe that you and everyone else can make all the right decisions if you receive correct and complete information. For this reason, since its establishment on March 6, 1971, Tempo has been and will always be committed to hard-hitting investigative journalism. For the public and the Republic.

Login Subscribe